Lineage plasticity: a new dilemma in lung cancer treatment
Molecular Biology Reports · 2026
DOI: 10.1007/s11033-026-11516-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2026. Verfasst von Cainan Huo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, Guangdong, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Cell Lineage, Cell Plasticity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 122 Literaturangaben. Gefördert von: Guangdong Medical University Undergraduate Innovation and Entrepreneurship Training Program, Guangdong Medical University Undergraduate Innovation and Entrepreneurship Education Base Project, Zhanjiang Non-funded Science and Technology Research Program Project.
Abstract (Originalsprache)
Lineage plasticity, the ability of cancer cells to switch lineages, is an emerging and critical mechanism of therapy resistance in lung cancer, posing a major obstacle to durable treatment responses. This review synthesizes the latest clinical and mechanistic advances to provide an integrated framework for understanding this phenomenon. We first explore the cellular origins and the “lineage-sharing” hypothesis, explaining how distinct histologic subtypes can arise from overlapping progenitor compartments. We then delineate how therapeutic pressure, through intratumoral competition and epigenetic reprogramming, drives the selection and expansion of resistant clones manifesting as histologic transformation (e.g., NSCLC to SCLC, adenocarcinoma-to-squamous) or phenotypic switching (e.g., within SCLC). A dedicated analysis dissects the core molecular networks, centered on EGFR, KRAS, TP53/RB1, MYC, and SOX2, that orchestrate these lineage changes. Crucially, we highlight the direct clinical implications of plasticity, linking it to aggressive disease progression and poor patient outcomes. Finally, we discuss persistent challenges and future perspectives, emphasizing the need for biomarkers for early detection and novel therapeutic strategies aimed at constraining plasticity to overcome resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, Guangdong, China.
- Department of Pathology, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
- The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China.
- Cancer Center, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, 523326, Guangdong, China. sunyanqin@gdmu.edu.cn.
- Department of Pathology, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, 523808, Guangdong, China. sunyanqin@gdmu.edu.cn.
Förderung
- Guangdong Medical University Undergraduate Innovation and Entrepreneurship Training Program
- Guangdong Medical University Undergraduate Innovation and Entrepreneurship Education Base Project
- Zhanjiang Non-funded Science and Technology Research Program Project
- Clinical and Basic Sci&Tech Innovation of Guangdong Medical University
- Guangdong Provincial Medical Science and Technology Research Fund
Zitieren
APA
Huo, C., Wang, Y., Li, R., Xie, X., Lyu, W., Chen, D., & Sun, Y. (2026). Lineage plasticity: a new dilemma in lung cancer treatment. Molecular Biology Reports. https://doi.org/10.1007/s11033-026-11516-4
Vancouver
Huo C, Wang Y, Li R, Xie X, Lyu W, Chen D, et al. Lineage plasticity: a new dilemma in lung cancer treatment. Molecular Biology Reports. 2026. doi:10.1007/s11033-026-11516-4
BibTeX
@article{Huo2026,
author = {Huo, Cainan and Wang, Yongxuan and Li, Rujia and Xie, Xiaofei and Lyu, Weiqi and Chen, Dingke and Sun, Yanqin},
title = {Lineage plasticity: a new dilemma in lung cancer treatment},
journal = {Molecular Biology Reports},
year = {2026},
doi = {10.1007/s11033-026-11516-4}
}
EUVIMED